Monitor May 7, 2026 earnings call for updated guidance on Brazil exposure and therapeutic registration progress. Assess whether new registrations materialize before the ban takes effect, as failure could materially impact future revenue.
Price Chart
Executive Summary
Phibro Animal Health disclosed a Brazilian regulatory ban on antimicrobial growth promoters including its virginiamycin and bacitracin products, effective after a 180-day transition period. The company expects limited FY2026 impact and is pursuing therapeutic registrations to mitigate long-term effects.
Key Facts
- Brazilian MAPA Ordinance No. 1617 prohibits use of virginiamycin and bacitracin as growth promoters effective 180 days from April 27, 2026.
- During transition period, sales and use under current labels continue.
- Phibro expects limited impact on fiscal year 2026 results.
- New registrations for therapeutic use of virginiamycin in cattle and broiler chickens are in final MAPA review and expected during transition.
- Bacitracin already carries therapeutic claims in Brazil.
- PhibroVet digital platform will facilitate veterinary prescriptions post-ban.
Financial Impact
Limited impact on FY2026 results; no specific dollar amounts provided.
Risk Factors
- Therapeutic registrations may not be approved before the ban takes effect, leading to revenue loss in Brazil.
- Other markets could adopt similar restrictions on antimicrobial growth promoters.
- Uncertainty about the magnitude of long-term financial impact beyond FY2026.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-049485 |
| Document: tm2612861d1_ex99-1.htm | 0001104659-26-049485 |
| Document: 0001104659-26-049485-index-headers.html | 0001104659-26-049485 |
| Document: 0001104659-26-049485-index.html | 0001104659-26-049485 |
| Document: 0001104659-26-049485.txt | 0001104659-26-049485 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 28, 2026 9w ago | 8-K | $36.95 $36.09 | ▼ −2.33% | ▼ −7.35% | $37.24 (+0.78%) |
Jun 26, 2026 14w ago | 8-K | $31.81 $34.04 | ▲ +6.99% | ▲ +7.27% | $37.24 (+17.07%) |
May 6, 2026 21w ago | 8-K | $43.16 $31.79 | ▼ −26.34% | ▼ −29.48% | $37.24 (−13.72%) |
May 5, 2026 21w ago | 8-K | $58.50 $31.79 | ▼ −45.66% | ▼ −48.44% | $37.24 (−36.34%) |
Apr 30, 2026 22w ago | 8-K | $54.66 $29.74 | ▼ −45.58% | ▼ −50.85% | $37.24 (−31.87%) |
Apr 27, 2026 22w ago | 8-K | $54.29 $33.68 | ▲ +37.96% | ▲ +43.43% | $37.24 (+31.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access